๐๏ธ Verified NIH Record โข Updated 2022-03-02
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (NCT04053803)
An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-ฮฒ0 Thalassemia) Who Participated in Study IMR-SCD-102
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: Imara, Inc.
๐ฉบ Plain-English Summary (8th-Grade Level)
This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
Who can join: Review the eligibility criteria below.
Location: University of Connecticut Health Center โ Farmington, Connecticut
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (7 Sites)
- University of Connecticut Health Center โ Farmington, Connecticut
- Foundation for Sickle Cell Disease Research โ Hollywood, Florida
- Baylor Scott & White Medical Center - Temple โ Temple, Texas
- Bristol Haematology and Oncology Centre โ Bristol,
- University College London Hospital NHS Foundation Trust โ London,
- Guy's and St Thomas Hospital CRF โ London,
- Royal London Hospital โ London,
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sickle Cell Disease
- Kidney Function in Sickle Cell Anemia โ Chapel Hill, North Carolina
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease โ Birmingham, Alabama
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease โ Bethesda, Maryland
- Acupressure in Patients With Sickle Cell Disease โ Irvine, California
- Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) โ Chicago, Illinois
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) โ Charlotte, North Carolina
Explore by condition: All Sickle Cell Disease clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.